# C. Neslusan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/c-neslusan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 955 |
| Field | Diabetes Treatment and Management |
| h-index | 12 |
| i10-index | 14 |
| Last Known Institution | Johnson & Johnson (United States) |
| OpenAlex ID | https://openalex.org/A5081762604 |
| ORCID iD | 0000-0002-9984-5905 |
| Works | 87 |

## Researcher papers

- [Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits](https://scholariq.org/papers/treating-allergic-rhinitis-in-patients-with-comorbid-asthma-the-risk-of-asthma/)
- [Explaining Drug Spending Trends: Does Perception Match Reality?](https://scholariq.org/papers/explaining-drug-spending-trends-does-perception-match-reality/)
- [Recent Antihyperglycemic Prescribing Trends for U.S. Privately Insured Patients With Type 2 Diabetes](https://scholariq.org/papers/recent-antihyperglycemic-prescribing-trends-for-u-s-privately-insured-patients/)
- [Lifetime benefits of early detection and treatment of diabetic kidney disease](https://scholariq.org/papers/lifetime-benefits-of-early-detection-and-treatment-of-diabetic-kidney-disease/)
- [Hospitalization and Total Medical Costs for Privately Insured Persons with Schizophrenia](https://scholariq.org/papers/hospitalization-and-total-medical-costs-for-privately-insured-persons-with/)
- [Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States](https://scholariq.org/papers/cost-effectiveness-analysis-of-canagliflozin-300-mg-versus-dapagliflozin-10-mg/)
- [Health care costs of allergic rhinitis-associated conditions vary with allergy season](https://scholariq.org/papers/health-care-costs-of-allergic-rhinitis-associated-conditions-vary-with-allergy/)
- [Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study](https://scholariq.org/papers/association-of-diabetes-related-kidney-disease-with-cardiovascular-and-non/)
- [Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico](https://scholariq.org/papers/cost-effectiveness-of-canagliflozin-versus-sitagliptin-as-add-on-to-metformin-in/)
- [Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.](https://scholariq.org/papers/cost-effectiveness-of-canagliflozin-versus-sitagliptin-when-added-to-metformin/)
- [Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data](https://scholariq.org/papers/development-and-internal-validation-of-a-discrete-event-simulation-model-of/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Medication Adherence and Compliance](https://scholariq.org/topics/medication-adherence-and-compliance/)
- [Mental Health Treatment and Access](https://scholariq.org/topics/mental-health-treatment-and-access/)

## Researcher university

- [Johnson & Johnson (United States)](https://scholariq.org/institutions/johnson-and-johnson-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.